Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06002633
Other study ID # R01AA030740
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 23, 2023
Est. completion date May 31, 2028

Study information

Verified date December 2023
Source University of Texas at Austin
Contact Research Coordinator
Phone 5124955198
Email behavioral.neuroimaging@austin.utexas.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Individuals with posttraumatic stress disorder (PTSD) have greater prevalence of alcohol use disorders (AUDs), with this comorbidity associated with worse illness outcomes, yet there remains limited mechanistic understanding of how PTSD confers risk for AUD. Understanding risk factors that associate with and predict the development of AUDs in PTSD could inform interventions and prevention efforts to reduce the rate of this comorbidity and improve outcomes of both disorders. Identifying predictors of risk requires longitudinal studies in PTSD aimed at capturing the mechanisms leading to the emergence of AUDs. There is growing evidence PTSD is related to biased decision-making during approach-avoidance conflict. Alcohol is also suggested to alter approach-avoidance decision-making. AUDs and acute alcohol intoxication is associated with a bias to seek out reward despite the possibility of threat (e.g., contributing to relapse following alcohol cue exposure and risky behavior during intoxication respectively). Alcohol-induced changes in approach-avoidance decision-making have not been investigated in the context of PTSD, but emerging data support the investigators' hypothesis that an interaction between alcohol and approach-avoidance conflict in PTSD may occur and contribute to risk for alcohol misuse and development of alcohol problems. No current data, cross-sectional or longitudinal, have tested the role of alcohol-induced changes in approach-avoidance conflict as a mechanism of risk for AUD among individuals with PTSD. To address this gap, the investigators propose to leverage the group's expertise in placebo-controlled alcohol administration procedures, longitudinal modeling, functional neuroimaging, and computational neuroscience approaches to investigate the effects of acute alcohol on approach-avoidance decision-making and mediating changes in multivariate neurocircuitry patterns in limbic, striatal, and salience networks.


Description:

The proposed study will test the conceptual model positing that acute alcohol alters the relative bias in computational mechanisms for threat vs reward, thereby decreasing avoidance to threat and increasing approach to reward in adults with PTSD, and through this mechanism increases risk for heavier alcohol use over time. Research aims are to identify alcohol-induced changes in approach-avoidance decision-making and mediating neural networks that predict alcohol use and symptoms of AUDs over a one-year follow-up period in adults with PTSD, compared to adults with interpersonal violence exposure but no PTSD and healthy comparison adults. Essential to successfully improving clinical prognosis in PTSD are research results that enable better prediction, diagnosis, and treatment based on the individual. There is a paucity of human clinical research investigating interactions between acute alcohol exposure and PTSD that may drive risk for development of AUDs following trauma. Data could identify brain and behavioral mechanisms explaining how alcohol alters an important domain of PTSD contributing to risk for alcohol misuse and development of alcohol problems. Results could pave way for development of novel behavioral and pharmacological methods to treat PTSD and decrease risk for developing comorbid AUDs.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date May 31, 2028
Est. primary completion date May 31, 2028
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years to 60 Years
Eligibility 1. Inclusion criteria for all participants: - between 21 and 60 years of age - having consumed at least 4 (men) or 3 (women) drinks on at least two occasions over the last year 2. Inclusion criteria for PTSD participants: - Meeting diagnostic criteria for PTSD, confirmed by structured interview 3. For all subjects exclusion criteria include: - history of significant medical illness, particularly if possible changes in cerebral tissue - neurologic abnormality including significant head trauma (loss of consciousness of =5-min) - full Scale IQ <85 - contraindication to MRI scanning - positive pregnancy test - severe alcohol use disorder - current severe cannabis use disorder - any current substance use disorder (other than alcohol, cannabis, or nicotine) - scores > 15 on the alcohol Use Disorders Identification Test (AUDIT; part of phone screen) - ever being in an abstinence-oriented treatment program for alcohol use - reporting wanting to quit drinking but not being able to - any medical, religious, or other reasons for not drinking alcohol - history of heart attack, heart trouble, high blood pressure, diabetes, or liver disease - an adverse reaction to alcoholic beverages - reporting never consuming 4 (men) or 3 (women) or more drinks on at least two occasions over the last year - unwillingness to have a friend or family member drive them home after the alcohol administration sessions 4. Additional exclusion criteria for participants in PTSD and IPV-exposed but no PTSD groups: - not taking medications for >4 weeks (i.e. participants must be stable on meds) - acute suicidality with intent 5. Additional exclusion criteria for participants in IPV-exposure but no PTSD group: - history of PTSD 6. Additional exclusion criteria for healthy comparison subjects also include: - any prior psychiatric hospitalizations - lifetime history of a neurodevelopmental disorder, affective disorder, psychotic disorder, suicide attempt, or eating disorder - greater than 1 month of lifetime psychotropic medication

Study Design


Intervention

Other:
Alcohol
Participants will consume beverages containing alcohol.
Placebo
Participants will consume beverages containing a very low dose of alcohol (placebo condition).

Locations

Country Name City State
United States University of Texas at Austin Austin Texas

Sponsors (1)

Lead Sponsor Collaborator
University of Texas at Austin

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary ratio of approach to avoidance choices the number of trials on which individuals chose to avoid vs approach will be quantified during the task and compared between placebo and alcohol conditions 1 week
Primary changes in dorsal anterior cingulate cortex activation the degree of activation on high conflict trials (relative to low conflict trials) on the task in the dorsal anterior cingulate will be quantified and compared between the placebo and alcohol conditions 1 week
Primary Relations between ratio of approach to avoidance choices with alcohol use over a one-year follow-up The relationship between the number of trials on which individuals chose to avoid vs approach during the alcohol session with alcohol use over a one-year follow up will be modeled. Number of drinks consumed per day over the course of the follow-up year will be used to calculate Area Under the Curve (AUC), with AUC as the dependent variable. 1 year
Primary Relations between changes in dorsal anterior cingulate cortex activation with alcohol use over a one-year follow-up The relationship between the degree of activation on high conflict trials (relative to low conflict trials) on the task in the dorsal anterior cingulate during the alcohol session with alcohol use over a one-year follow up will be modeled. Number of drinks consumed per day over the course of the follow-up year will be used to calculate Area Under the Curve (AUC), with AUC as the dependent variable. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04317820 - Deep Brain Reorienting in Post-traumatic Stress Disorder N/A
Completed NCT05112003 - Translingual Neurostimulation for the Virtual Treatment of Post-Traumatic Stress Disorder: A Feasibility Pilot N/A
Recruiting NCT04518267 - Anger and Psychotrauma: Data From Military and Civilians
Completed NCT02502604 - Cognitive Training Program for Individuals With Depression and Post-Traumatic Stress Disorder N/A
Completed NCT02256566 - Cognitive Training for Mood and Anxiety Disorders N/A
Terminated NCT02234687 - A mGlu2/3 Agonist in the Treatment of PTSD Phase 1
Terminated NCT02520726 - PTSD Prevention Study Examining the Efficacy of Sertraline in Burn Victims Phase 4
Completed NCT01738308 - The Effects of Healing Touch on Post Operative Pediatric Patients N/A
Completed NCT02213900 - Preventing Post-Operative Delirium in Patients Undergoing a Pneumonectomy, Esophagectomy or Thoracotomy Phase 4
Completed NCT01437891 - Sentra AM® and Sentra PM® for Post-traumatic Stress Disorder (PTSD) and Gulf War Fibromyalgia (GWF) N/A
Completed NCT01517711 - Tramadol Extended-Release (ER) for Posttraumatic Stress Disorder (PTSD) Phase 4
Completed NCT01199107 - Maximizing Treatment Outcome and Examining Sleep in Post-traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01998100 - Maximizing Treatment Outcome in Post-Traumatic Stress Disorder (PTSD) Phase 3
Completed NCT01231711 - Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention Phase 1
Completed NCT00348036 - Group Intervention for Interpersonal Trauma N/A
Completed NCT00680524 - Telephone-based Care for OEF/OIF Veterans With PTSD N/A
Completed NCT00838006 - Psychophysiologic Predictors of Post-deployment Mental Health Outcomes N/A
Completed NCT00525226 - Evaluating the Effects of Stress in Pregnancy N/A
Completed NCT00127673 - Comparison of Two Treatments for Post-Traumatic Stress Disorder Phase 3
Completed NCT00158262 - Effect of Propranolol on Preventing Posttraumatic Stress Disorder Phase 4